A PHASE I/II OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF OP-1250 MONOTHERAPY IN ADULT SUBJECTS WITH ADVANCED AND/OR METASTATIC HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE BREAST CANCER
- Registry ID
- OP-1250-001
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- OLEMA PHARMACEUTICALS, INC.
- Last update
- 2021-02-03
Conditions
- BREAST CANCER, HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC
Related clinical trials
- AN OPEN-LABEL, MULTI-CENTER, PHASE I/IB STUDY OF IEV407 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO PLUS A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH ENDOCRINE-SENSITIVE PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER.
- AN OPEN-LABEL, RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF-07220060 + LETROZOLE VS CDK4/6 INHIBITOR+ LETROZOLE IN PARTICIPANTS>18 YEARS OF AGE WITH HR-POSITIVE, HER2-NEGATIVE
ADVANCED/METASTIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC TREATMENT.
- A PHASE 2, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY OF BELZUTIFAN PLUS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER PROGRESSION ON PREVIOUS ENDOCRINE THERAPY (LITESPARK-029)
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)
- AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR¿S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)
View on source registry